RAB22A: A Potential Drug Target and Biomarker for Ras-Induced Cancer

Target Name: RAB22A

NCBI ID: G57403

RAB22A

Other Name(s): Ras-related protein Rab-22A | RAB22 | Rab-22 | GTP-binding protein RAB22A | MGC16770 | RB22A_HUMAN | RAB22A, member RAS oncogene family | rab-22

RAB22A: A Potential Drug Target and Biomarker for Ras-Induced Cancer

Abstract:

Ras-related protein Rab-22A has been identified as a potential drug target and biomarker for cancer. Its functions in cell signaling pathways have been extensively studied, and its role in cancer development and progression is still being explored. This review article aims to summarize the current understanding of Rab-22A, its potential drug targets, and its potential as a biomarker for cancer.

Introduction:

Ras (Ras-related protein) is a transmembrane protein that plays a crucial role in cell signaling pathways. It is a member of the G protein-coupled receptor (GPCR) family and is involved in various signaling pathways, including cell survival, angiogenesis, and inflammation. The identification of Rab-22A, a protein that is highly homologous to Ras, has raised the possibility that it may serve as a drug target or biomarker for cancer.

Functional and Anticancer Properties of Rab-22A:

Rab-22A is a 22-kDa protein that is highly homologous to Ras. It is expressed in various tissues and cell types and is involved in various signaling pathways, including cell survival, angiogenesis, and inflammation. In addition to its role in cell signaling pathways, Rab-22A has also been shown to have anticancer properties.

For example, studies have shown that Rab-22A can inhibit the growth of various cancer cell types, including human breast cancer cells. Additionally, Rab-22A has been shown to reduce the migration and invasion of cancer cells. These findings suggest that Rab-22A may be a useful drug target or biomarker for cancer.

Potential Drug Targets:

Several studies have identified potential drug targets for Rab-22A. One of the most promising targets is the protein p120, which is a GPCR-coupled receptor that is involved in cell signaling pathways. Studies have shown that p120 is a good candidate target for a drug that inhibits Rab-22A activity.

Another potential drug target for Rab-22A is the protein S6, which is a GPCR-coupled receptor that is involved in cell signaling pathways. Studies have shown that S6 is a good candidate target for a drug that inhibits Rab-22A activity.

Potential Biomarkers:

Rab-22A has also been identified as a potential biomarker for cancer. Several studies have shown that Rab-22A is expressed in various tissues and cell types, including cancer cells. Additionally, studies have shown that Rab-22A has been shown to be involved in various signaling pathways, including cell signaling pathways that are involved in cancer development and progression. These findings suggest that Rab-22A may be a useful biomarker for cancer.

Conclusion:

In conclusion, Rab-22A is a protein that is highly homologous to Ras and has been shown to have various functions in cell signaling pathways, including cell survival, angiogenesis, and inflammation. Its potential as a drug target or biomarker for cancer is still being explored. Further research is needed to fully understand the role of Rab-22A in cancer development and progression.

Protein Name: RAB22A, Member RAS Oncogene Family

Functions: Plays a role in endocytosis and intracellular protein transport. Mediates trafficking of TF from early endosomes to recycling endosomes (PubMed:16537905). Required for NGF-mediated endocytosis of NTRK1, and subsequent neurite outgrowth (PubMed:21849477). Binds GTP and GDP and has low GTPase activity. Alternates between a GTP-bound active form and a GDP-bound inactive form (PubMed:16537905)

The "RAB22A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB22A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets